Pharmacogenomic testing has been widely available for over a decade to help guide pharmacotherapy including antidepressant selection when treating major depressive disorder. Yet, the data hasn’t substantiated improved safety or efficacy. Host Geoff Wall is joined by Sarah Grady, PharmD to evaluate the PRIME study looking at the role of pharmacogenomic testing in depression.
The GameChanger
Pharmacogenomic testing may help decrease adverse effects at 12 weeks, but not 24 weeks. However, the study did identify a potential confounder with L-methylfolate deficiency.
Show Segments
00:00 – Introductions
02:15 – Background on Pharmacogenomic Testing
05:15 – PRIME Care Study
18:10 – Connecting to Practice
20:55 – Gamechanger
22:12 – L-methylfolate Deficiency Treatment
26:25 – Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Guest
Sarah Grady, PharmD
Professor of Pharmacy Practice, Drake University
References and resources:
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
Redeem your CPE or CME credit
Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Continuing Education Information:
Learning Objectives:
1. Describe the outcomes and limitations of the PRIME care study
2. Discuss the role of L-methylfolate in the treatment of depression
All relevant financial relationships have been mitigated.
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-305-H01-P
Initial release date: 09/05/22
Expiration date: 09/05/2023
Additional CPE & CME details can be found here